Formation Bio announced a $600M fund it will use to acquire 10–15 drug programs over the next 3–5 years - it is a step in its plan to make drug development more efficient and become 'the next pharma'
Co-Founder and CEO Ben Liu describes the fund, and explains why Formation chose this structure rather than doing an equity raise. He also explains Formation's approach to drug development, the types of assets it likes to look for, why a smaller company might be more nimble than larger pharmas today, and the Formation's lofty long-term ambitions.
1 day ago
Zentalis aims to deliver to the ovarian cancer community a precision medicine approach - a targeted (WEE1) oral therapy for patients who are Cyclin E1 positive
CEO Julie Eastland describes the WEE1 target and data the company has recently presented at ESMO showing a benefit in Cyclin E1 positive patients. 2027 will be a big year as key trial reads out and discussions with FDA determine whether the company will go for an accelerated or full approval as the next step.
1 day ago
BIO-Europe 2026: Bionyra Pharma emerged from stealth earlier this year with $165m in series A financing and three in-licensed assets: a TL1A Mab, a TL1A*IL-23p19 bispecific, and an IL-25 Mab
CEO and co-founder Frédéric Marrache tells us that half-life extension technology should bestow important differentiation on the company’s TL1A assets, versus more advanced, similar projects in development elsewhere. He also believes that IL-25 could become an important new mechanism for atopic dermatitis. Coverage brought to you by
1 day ago
BIO-Europe 2026: Abalos Therapeutics will have p1 data on its lead project in 1H27, a non-oncolytic arenavirus-based product that is being tested in refractory/relapsed solid tumors
CEO Gerben Moolhuizen tells us how the company has developed an arena-virus based platform that allows for systemic delivery, and a more targeted approach than other virus-based immunotherapies. Coverage brought to you by
2 days ago
STIFEL 2026: Trace Neuroscience believes that a breakthrough in ALS will be due to restoring expression of a protein called UNC13A, which most ALS patients don't have sufficient due to genetic factors
Co-Founder and CEO Eric Green explains the role of UNC13A, and how UNC13A mRNA is improperly spliced for most ALS patients. Trace is currently running a UK/EU phase 1 study of its antisense oligonucleotide that aims to restore expression, and also concurrently an investigator led study in China. Coverage brought to you by
2 days ago
STIFEL 2026: Oruka's IL-23p19 is showing strong efficacy in p2 psoriasis studies compared to existing products and might be dosed as little as once or twice a year - a key update will read next month
CEO Lawrence Klein describes the data that has been seen so far (clearance in the 60% range at 16 weeks) and previews with upcoming 52 week data that will be coming in December. Plus, how the company is thinking about phase 3 design, and other assets in the pipeline. Coverage brought to you by
2 days ago
STIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months
CEO Neil Warma describes ProMIS's approach of targeting amyloid beta oligomers as opposed to the plaques. He explains how so far they have avoided the ARIA (brain swelling) seen with other Alzheimer's treatments and discusses what the company hopes to see from this phase 1b study. Plus, comments on the recent failure of another company in this space. Coverage brought to you by
2 days ago
STIFEL 2026: With expertise in the next generation of GPCR development, Septerna will have initial human data on its oral PTH1R agonist for hypoparathyroidism in Q1
Co-Founder & CEO Jeff Finer walks us through the company's GPCR discovery platform, and discusses, this lead program, a new target (TSHR) they just named in Grave's disease and thyroid eye disease, and the company's work in obeisty with partner Novo Nordisk. Coverage brought to you by
2 days ago
STIFEL 2026: Rapport Therapeutics' CEO Abe Ceesay highlights the company's recent phase 2 success for RAP-219 in bipolar mania and discusses the next steps ahead
He describes the company's precision mechanism, and discussions they will have with FDA before starting phase 3 trials in this indicuation next year. Plus, previewing long-term data that will be out soon in epilepsy. Coverage brought to you by
2 days ago
STIFEL 2026: REGENXBIO will have its pivotal studies for wet AMD read out before the end of the year - combined, they are the largest study of a gene therapy ever
CEO Curran Simpson sets the table for the readouts and describes what he believes they need to show in order to succeed. Plus, updates on the DMD program and RGX-121. Coverage brought to you by
3 days ago
BIO-Europe 2026: CEO Alan Barge describes 4CBiomed's lead asset, which acts against a novel checkpoint target, 4CB1
The company is trying to raise a $20m series A to take the project into phase 1 trials. Coverage brought to you by
3 days ago
BIO-Europe 2026: Epitopea has just started dosing patients in the first clinical trial of its RNA-based cancer vaccine
CEO Alan Rigby tells us about the program, and says data should start emerging next year. Coverage brought to you by
3 days ago
STIFEL 2026: Compugen has a trial in ovarian cancer for its PVRIG scheduled to read out in the early part of 2027 - later that year brings the start of Astra's big readouts with the TIGIT bispecific
CEO Eran Ophir defines what would be a success in the ovarian trial and possible next steps if successful. Plus, TIGIT, Gilead's work on IL18, and looking for new T-cell engager targets. Coverage brought to you by
3 days ago
STIFEL 2026: Cullinan Therapeutics' CEO Nadim Ahmed gives an overview of the progress of the company's T-cell engagers in autoimmune and oncology (and more)
He goes over a partner's BCMA data that was just presented this weekend at ACR in lupus, and previews a key CD19 update that Cullinan will be providing investors in December. Plus, he comments on zipalertinib, which is in front of FDA now in two lines of therapy. Coverage brought to you by
3 days ago
STIFEL 2026: Over the last two weeks, Marengo Therapeutics has published landmark data on its Vβ-directed platforms in Nature Medicine, and presented new clinical data in breast cancer at SITC
CEO Zhen Su describes the platform and walks us through the SITC data, which was given on top of Trodelvy. Coverage brought to you by
3 days ago
STIFEL 2026: Alkermes' new CEO Blair Jackson describes his priorities for the company - which include a heavy focus on the emerging orexin agonist class
He describes the profile of the company's orexins and their development path (a key trial in Idiopathic Hypersomnia will be reading out soon), which also includes indications like ADHD, MS, and Parkinson's further on down the line. Plus how the acquisition of Avadel has been a fit, and whether he would consider doing additional deals. Coverage brought to you by
3 days ago
STIFEL 2026: Korsana Biosciences is using a proprietary brain shuttle and a beta amyloid targeting therapy and aims to take Alzheimer's treatment to the next level
President and CEO Jonathan Violin compares and contrasts his product with other brain shuttles and discusses the road ahead. They will present preclinical data at CTAD next week and the clinical program will ramp up and have initial data in 2027. Korsana recently went public through a reverse merger. Coverage brought to you by
3 days ago
BIO-Europe 2026: Envisagenics is harnessing RNA splicing as its therapeutic approach - which may open up biology to novel targets
Co-Founder & CEO Maria Pineda describes the idea behind RNA splicing, which the company is using initially against (currently unnamed) CNS and oncology targets. It also recently announced a multi-target collaboration with Boehringer Ingelheim for oncology. Coverage brought to you by
4 days ago
BIO-Europe 2026: Atrogi aims to harness beta-2 agonism to increase muscle mass for a whole host of conditions, including muscle loss due to GLP medicines
CEO Paul Little talks about the benefits of muscle strength and mass, and why Atrogi thinks beta-2 agonism is a good way to improve it - and why he believes their approach has engineered any potential safety issues out. Coverage brought to you by:
4 days ago
BIO-Europe: The FDA decision date for Hansa's IgG-inactivating therapy for kidney transplant patients is coming up on December 19th
CEO Renée Aguiar-Lucander describes the unmet need for a therapy like this, and discusses how Hansa has been preparing for this decision date well in advance. Coverage brought to you by
4 days ago
BIO-Europe 2026: Belgium based MRM Health believes its optimization method for microbiome treatments sets it apart - a key readout next year in UC will be a window into its potential
CEO Sam Possemiers describes the platform and discusses the lead program in ulcerative colitis, which is currently in a phase 2 study that will read out late next year. Coverage brought to you by
5 days ago
From Montreal: Congruence Therapeutics uses computational discovery to develop novel small molecule correctors and allosteric modulators - its lead program is for a high profile genetic obesity target
Founder & CEO Clarissa Desjardins describes Congruence's Revenir product engine and walks us through programs that include MC4R deficient obesity, which is in the clinic, alpha-1 antitrypsin deficiency, and Parkinson's.
Nov 6
Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B
CEO Rohit Batta describes the unmet need in myeloproliferative neoplasms and the rational for targeting G6B, a protein expressed on platelets and megakaryocytes. Their pre-clinical work just earned Alethio an oral presentation at the upcoming ASH Annual Meeting.
Nov 5
From Montreal: Ocythera is developing a treatment for rare bone disorders that targets the retinoic acid pathway without using retinoids
Interim CEO Joseph Mancini describes how Ocythera's solution inhibits an enzyme and how this approach has shown to not have the toxicity issues in preclinical studies that retinoids have seen. Plus, how Montreal's adMare BioInnovations has been critical to Ocythera's early work.
Nov 4
From Montreal: Find Therapeutics is developing transmembrane directed peptides - its initial testing of this platform that could have wide utility is in demyelinating diseases like MS
CMO Robert Glanzman describes the platform, which originated at the University of Strasbourg, and why they chose MS as the lead program. They have already tested it in healthy volunteers in phase 1 and are currently preparing for a phase 2 study. Find is an example of a company that has benefited from Montreal's adMare BioInnovations.
Nov 4
Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC
CEO Sarah Leonard describes the company's focus and process. The lead program, TC25, is scheduled to be in the clinic in 2028, and the company also has plans to go after auto-immune conditions in addition to oncology.
Nov 3
Roman Giverts, CEO of Vumedi, a peer-to-peer video platform for physicians that offers the latest on trials and practice trends, says that physicians are looking for deeper insights than today's AI
He hears from his users about the limitations of AI today, which include that bots are crawling literature that does not fit every unique patient - he says judgement matters.
Nov 2
After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)
President and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses plans for a phase 3 in first line (plus the regulatory path for later lines as well). Additionally, he discusses using PRMT5 inhibition in lung cancer and GBM.
Oct 29
.png){kind=logo}
